Apitope International NV is a biopharmaceutical company with its head office in Diepenbeek, Belgium, and a subsidiary in Bristol, United Kingdom. The company develops trail-blazing products with substantial therapeutic benefits aimed at crucial, unmet needs that may revolutionise the treatment of chronic auto-immune diseases and allergic conditions. Both types of illness are caused by an inappropriate reaction by the patient’s immune system to his own (auto-immune) or outside (allergic) antigens.
In mid-2008 LRM and Vesalius Biocapital took the lead in an investment round of 10 million euro. This round was also subscribed to by Fast Forward (US), VINNOF (Be), University of Hasselt (Be), The Wellcome Trust (UK), the Daniels family (UK), Wyvern Seedcorn Fund (UK) and the University of Bristol (UK). UHasselt is also Apitope’s R&D-partner and contributed technology to this round, as well as capital.